Buradasınız

Anasayfa » Content

RENAL ALLOGREFT ALICILARINDA HÎPERLÎPÎDEMÎNÎN GEMFÎBROZÎLLE SAĞALTIMI

TREATMENT OF HYPERLIPIDEMIA IN RENAL ALLOGRAFT RECIPIENTS WITH GEMFIBROZIL

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Experience on medical treatment of hyperlipide-mia, which is a frequent metabolic derangement in transplant recipients, is limited. After it has been an¬nounced that lovastatin causes rh.abdomyolisis, the safety has also become a subject of discussion. Twenty-five cases of whom graft ages were > 9 monhts, creatinin levels were < 2 mgldl and following a diet of 6 months duration triglyceride levels (TG) were 2200 mgldl and/or total cholesterol (TC) were enrolled in this prospective study. Among them, 14 hyperlipidemic patients were given gemfibrozil 2x600 mgldfor 3 months; control group consisted of the ot¬her 11 patients. At the end of 3 months, TG decreased from 218±49 mgldl to 136 ± 35 TC from 238±22 mgldl to 206±20, LDL-C 138±24 mgldl to 125±17; HDL-C increased from 48±10 mgldl to 55 ±10. There was no significant change in the control group. No si¬de effect that required to cancel the treatment had be¬en observed during the study. In conclusion, gemfib-rozil is thought to be a safe and effective drug in the treatment of hyperlipidemia of renal allograft recipi¬ents.
Bookmark/Search this post with
Abstract (Original Language): 
Transplant alıcılarında sık görülen hiperlipidemi-nin ilaçla sağaltımı konusunda deneyimin sınırlı olması yanışım, lovastatinin rabdomiyolize yol açabil-diğinin bildirilmiş olması sağaltımın güvenilirliğini de tartışılu kılmıştır. Bu prospektif çalışmada greft yaşı > 9 ay ve kreatinin < 2 mgldl (176.8 mmollL) olup, 6 ay diyet sonrası trigliserid (TG) > 200 mgldl (2.26 mmol/L) ve/veya total kolesterol (TK) > 220 mgldl (5.68 mmol/L) olan 25 olgudan 14'üne 3 ay sü¬reyle 2x600 mg/gün dozunda gemfibrozil (GF) verilir¬ken, diğer ll'i kontrol (K) grubu olarak izlenmiştir. Üç ay sonunda GF grubunda TG 218149 mgldl (2.46±0.55 mmollLYden 136 ±35 mgldl (1.53 ± 0.39 mmollLYye TK 238 ± 22 mgldl (6.14 ± 0.56 mmollLYden 206 ±20 mgldl (5.32 ±0.51 mmollLYye LDL-K138 ± 24mgldl (3.56± 0.62 mmollLYden 125 ±17 mgldl (3.22 ± 0.43 mmollLYye düşerken, HDL -K 48 ±10 mgldl (1.24 ± 0.25 mmollLYden 55 ± 10 mgldl (1.42 ± 0.25 mmollLYye yükseldi. K grubunda ise bu parametrelerde anlamlı değişiklik olmadı. Sa¬ğaltımın kesilmesini gerektirir yan etki saptanmadı. Gemfibrozilin renal allogreft alıcılarında hiperlipide-mi sağaltımında etkin ve güvenilir olduğu düşünüldü.
FULL TEXT (PDF): 
PDF icon pdf_tndt_90.pdf
  • 2
111-114
  • Turkish

REFERENCES

References: 

1. Bagdadc JD. Albcrs JJ. Plasma high density lipoprotein concentrations in chronic hemidialysis and renal irans-plani patients. N Engl Med 1977; 296: 1436-1439.
2. Carlson LA, Aberg H. Serum triglycerides: An indepen-dcni risk factor lor myocardial infarction bui not for angina pccioris. N Engl J Med 1985; 312: 1127-1131.
3. Catiran DC. Sterner G. Wilson DR, et al. Hyperlipidc-mia after renal transplantation: Natural hislory and pathophysiology. Ann Intern Med 1979; 91: 554-559.
4. Chan MK. Varghcsc Z, Pcrsaud JW, cl al. The role of multiple pharmacotherapy in the pathogenesis of hyper?' lipidemia afler renal transplantation. Clin Nephrol 1981; 15:309-313.
5. Chan MK. Zaehariah V. Moorhcad JF. Lipid abnormalities in uremia, dialysis, and transplanlalion. Kidney Int 1981; 19: 615-637.
6. Chan T M, Cheng İKİ1, Tam SCF. Hypcrlipidetnia aficr renal transplantation: Treatment with gcmhfibroz.il. Nephron 1994; 67:317-321.
7. Corpier JL. Jones PH. Suki WN el al. Rhabdomyolisis and renal injury with lovaslatmn use. JAMA 1988; 260: 239-241.
8. Dişler PB. Goldberg RR, Klin L, el al The role ol diet in Ihe pathogenesis and control öf hypcılipidcniia aftci renal transplantation. Clin Nephrol I9R1; M>: 29 W
9. Grundy SM. Vega L. Fifoic acids: Effect.1! on 1 i lipoprotein metabolism Am J Med I987i}t3 ' !U
113
10. Keogh A, Doy R, Critchely L, et al. The effect of food and cholestyramine on the absorbiion of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20: 27-30.
11. Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982; 34: 347-351.
12. Knight RJ, Vathsala A, Schoenberg L, et al. Treatment of hyperlipidemia in renal transplant patients with gem-fibrozil and dietary modification. Transplantation 1992;
53: 224-225, 1992.
13. Lowrie EG, La/ans JM. Mocelin AT. et al. Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med 1973 288: 863-867.
14. Ponlicelli C.
B.ırb
i GL, Canlaluppi A, el al. Lipid viisoı ders in renal transplant recipients. Nephron 197-8; 20: 189-195.

Thank you for copying data from http://www.arastirmax.com